Novavax, Inc. 2025 Q4 - Results - Earnings Call Presentation

Novavax reported Q4 2025 earnings with EPS of $0.11, surpassing analyst expectations by $0.69, marking a significant financial beat amid ongoing market volatility. Revenue reached $147.14 million, a 66.61% year-over-year increase and $57.28 million above projections, signaling strong demand for its vaccine portfolio. The earnings call slide deck highlighted operational improvements, including streamlined production and expanded global distribution partnerships for its updated COVID-19 and flu vaccines. Management emphasized R&D progress, with late-stage trials for next-gen vaccines targeting emerging variants, positioning Novavax for long-term growth in infectious disease prevention. Investors reacted positively to the results, reflecting confidence in the company’s turnaround strategy and pipeline advancements after prior financial struggles.